Current and historical daily PE Ratio for Molecular Partners AG (
) from 2018 to Jun 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Molecular Partners AG stock (MLLCF) PE ratio as of Jun 23 2024 is 0.
More Details
Molecular Partners AG (MLLCF) PE Ratio (TTM) Chart
Molecular Partners AG (MLLCF) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1254
- 1
- 2
- 3
- 4
- 5
- 6
- 14
Molecular Partners AG PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-23 | At Loss | 2024-04-18 | At Loss |
2024-06-21 | At Loss | 2024-04-17 | At Loss |
2024-06-20 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-20 | At Loss | 2024-03-15 | At Loss |
2024-05-17 | At Loss | 2024-03-14 | At Loss |
2024-05-16 | At Loss | 2024-03-13 | At Loss |
2024-05-15 | At Loss | 2024-03-12 | At Loss |
2024-05-14 | At Loss | 2024-03-11 | At Loss |
2024-05-13 | At Loss | 2024-03-08 | At Loss |
2024-05-10 | At Loss | 2024-03-07 | At Loss |
2024-05-09 | At Loss | 2024-03-06 | At Loss |
2024-05-08 | At Loss | 2024-03-05 | At Loss |
2024-05-07 | At Loss | 2024-03-04 | At Loss |
2024-05-06 | At Loss | 2024-03-01 | At Loss |
2024-05-03 | At Loss | 2024-02-29 | At Loss |
2024-05-02 | At Loss | 2024-02-28 | At Loss |
2024-05-01 | At Loss | 2024-02-27 | At Loss |
2024-04-30 | At Loss | 2024-02-26 | At Loss |
2024-04-29 | At Loss | 2024-02-23 | At Loss |
2024-04-26 | At Loss | 2024-02-22 | At Loss |
2024-04-25 | At Loss | 2024-02-21 | At Loss |
2024-04-24 | At Loss | 2024-02-20 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
Molecular Partners AG (MLLCF) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Molecular Partners AG Molecular Partners AG logo](https://static.gurufocus.com/logos/0C0000AR9M.png?14)
Molecular Partners AG
ISIN : CH0256379097
Compare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USA0QXX.UK6ML0.Germany IPO Date
2018-06-14Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.